Adicet Bio to Participate in a Fireside Chat at the Guggenheim 2nd Annual Healthcare Innovation Conference

Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced that Chen Schor, President and Chief Executive Officer, will participate in a fireside chat at the Guggenheim 2nd Annual Healthcare Innovation Conference being held from November 10-12, 2025 in Boston.

Details of the event are as follows:

Date: Tuesday, November 11, 2025

Time: 3:00 p.m. ET

The live audio webcast can be accessed on the Investors section of Adicet Bio’s website at http://www.adicetbio.com. An archived replay will be available for 30 days following the presentation.

About Adicet Bio, Inc.

Adicet Bio, Inc. is a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer. Adicet is advancing a pipeline of “off-the-shelf” gamma delta T cells, engineered with chimeric antigen receptors (CARs), to facilitate durable activity in patients. For more information, please visit our website at https://www.adicetbio.com.

Contacts

More News

View More

Recent Quotes

View More
Symbol Price Change (%)
AMZN  207.94
+0.02 (0.01%)
AAPL  266.38
-6.56 (-2.41%)
AMD  198.67
-5.01 (-2.46%)
BAC  49.72
-2.58 (-4.94%)
GOOG  305.59
-1.56 (-0.51%)
META  640.31
-16.70 (-2.54%)
MSFT  393.50
-8.22 (-2.04%)
NVDA  179.13
-5.76 (-3.12%)
ORCL  143.66
-6.65 (-4.42%)
TSLA  400.12
-8.46 (-2.07%)
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.